we recently compiled a list of the 10 Most Undervalued Quality Stocks To Buy According To Analysts. In this article, we will look at where Alkermes (NASDAQ:ALKS) ranks among the most undervalued ...

EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.

Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company based in Ireland. It develops and manufactures medicines for mental health, neurological conditions, and cancer.

The stock price of Alkermes, a biopharmaceutical company focused on neuroscience and oncology, has seen a rise of around 16% over the last twenty-one trading days, and it is up a solid 91% over ...

Alkermes Price Performance. Spin-Off Research. Post-spin-off, Alkermes (RemainCo) will retain its focus on significant unmet needs within neuroscience and driving the growth of its proprietary ...

View the latest Alkermes PLC (ALKS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Alkermes expects that revenue for full-year 2021 will be between $1.1 billion and $1.17 billion. It anticipates GAAP loss per share of $0.53 to $0.78, with adjusted non-GAAP EPS between $0.37 and ...

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss the company's first quarter financial results.

Alkermes reported slightly weaker-than-expected Q1 results several weeks ago, and the stock quote is down close to -30% since February. The good news for investors is the company: (1) ...